Abstract: Novel compounds of the following general formula or salts thereof. wherein Ring M is a heterocyclic ring having —N═C<, —CO—N< or —CS—N< as the partial structure —X{overscore (— — — — — — — — —)} Y<; Ra and Rb are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Rng C is optionally substituted homocyclic or heterocyclic ring; Rng Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has an excellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

Abstract: Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.CC<, --CO--N< or --CS--N< as the partial structure --X . . . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Ring C is optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has an excellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

Abstract: Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<, --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Ring C is optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has an excellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

Abstract: Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<, --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Rng C is optionally substituted homocyclic or heterocyclic ring; Rng Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has anexcellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

Abstract: Novel compound represented by the formula: ##STR1## wherein A", B, C, D, E, G, Ar, X, Y, and Z are defined herein or a salt thereof. The compounds have excellent activity of inhibiting ACAT, lowering Cholesterol in blood and inhibiting tachykinin receptor, or a salt thereof, their production and use.

Abstract: A novel compound represented by the formula: ##STR1## wherein Ring A and Ring B respectively stands for an optionally substituted homo- or hetero-cyclic ring, and at least one of them stands for an optionally substituted heterocyclic ring stand; Ring C stands for an optionally substituted benzene ring; R stands for a hydrogen atom or an optionally substituted hydrocarbon residue; one of X and Y stands for --NR.sup.1 -- (R.sup.1 stands for a hydrogen atom or an optionally substituted hydrocarbon residue) or --O--, and the other stands for--CO-- or --CS--, or one of them stands for --N.dbd. and the other stands for .dbd.CR.sup.2 -- (R.sup.2 stands for a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon residue, an optionally substituted amino group or an optionally substituted hydroxyl group); n denotes 1 or 2 or salts thereof which have an excellent tachykinin receptor antagonistic action and inhibitory action on plasma extravasation.

Abstract: Novel compound represented by the formula: ##STR1## such as 6-Chloro-N-(2,6-diethoxyphenyl)-4-(2-methylphenyl-2-oxo-2H-1-benzopyran-3- acetamide: ##STR2## or a salt thereof. The compound has an excellent activity of inhibiting ACAT, lowering the cholesterol in blood and inhibiting tachykinin receptor. The present invention also relates to the production and use of the disclosed compound.

Abstract: A compound of the formula ##STR1## wherein R.sup.1 is hydrogen or a hydrocarbon residue which may be substituted; R.sup.2 is oxo or hydrogen plus hydroxy which may be acylated; R.sup.3 is hydrogen or hydroxy which may be acylated; at least one of the dotted lines represents a single bond, or a salt thereof, produced from Penicillum thomii has potent RA-89 muscarinic receptor blocking activity and is of value as therapeutic agent for parkinsonism, ulcer, etc. or as mydriatics.

Abstract: The present invention relates to an aromatase inhibiting composition which contains a compound of the formula: ##STR1## wherein R is hydroxy, lower alkoxy or amino which may be substituted by lower alkyl; R.sup.1 is hydrogen or lower alkyl; and A is hydrogen, a group of the formula ##STR2## in which R.sup.2 is hydroxy, lower alkoxy or amino which may be substituted by lower alkyl and R.sup.3 is hydrogen or lower alkyl, or a group of the formula ##STR3## in which R.sup.4 and R.sup.5 are independently hydrogen or lower alkyl, or a salt thereof.The present composition is useful in the prevention and treatment of estrogen-dependent diseases, such as breast cancer.

Abstract: The compound of the formula: ##STR1## wherein R.sub.1 is hydrogen, methyl or hydroxymethyl, R.sub.2 is hydrogen or methoxy, R.sub.3 is hydroxy or methoxy, and R.sub.4 is hydrogen or a group ##STR2## is novel, and the compound is of use as inhibitors of animal tissue fibrosis, or biochemical reagents.

Abstract: Compounds of the formula ##STR1## wherein n is equal to zero or 1 and their physiologically acceptable salts are effective for the prophylaxis or treatment of the fibrosis due to excessive collagen accumulation in mammal.

Abstract: The compound of the formula: ##STR1## wherein R.sub.1 is hydrogen, methyl or hydroxymethyl, R.sub.2 is hydrogen or methoxy, R.sub.3 is hydroxy or methoxy, and R.sub.4 is hydrogen or a group ##STR2## is novel, and the compound is of use as inhibitors of animal tissue fibrosis, or biochemical reagents.